We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

A Solution for Aggregate Removal in Engineered mAbs

3D illustration of monoclonal antibodies binding to cell surface receptors, depicting targeted therapeutic action
Credit: iStock

As therapeutic antibody designs become increasingly engineered for higher efficacy, developers face growing challenges with elevated aggregate levels that compromise purification processes.


Traditional aggregate removal methods using cation exchange or hydrophobic interaction chromatography often result in poor process economics and low recoveries, while caprylic acid flocculation requires additional filtration steps that complicate workflows.


This poster presents an innovative resin-based approach using immobilized caprylic acid that effectively removes high levels of aggregates while simultaneously helping to reduce leached protein A ligand and hundreds of host cell proteins – all while maintaining excellent monomer yields in a simplified flow-through process.


Download this poster to learn:

  • How this novel mixed-mode resin outperforms traditional purification strategies for engineered antibodies
  • Optimal operational conditions determined through DoE studies that can help achieve >80% monomer yield with <2% aggregate levels
  • How implementing this approach can help improve process economics and enable intensified purification workflows

Pharmaceutical Grade Reagent. For Manufacturing and Laboratory Use Only.
Brought to you by

Download the Poster for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.